Tailoring Treatment Approaches in Psoriasis Management - Episode 5
Exploring Undertreatment of Psoriasis in Skin of Color
Panelists discuss how undertreatment remains pervasive in psoriasis management, with recent data from Gondo (2024) revealing that nearly one-third of patients with moderate to severe disease receive only over the counter (OTC), complementary, or topical therapies, while similarly high percentages of patients with mild disease but high-impact location involvement are undertreated, with disparities particularly affecting patients of color, those of lower socioeconomic status, and individuals whose limited body surface area (BSA) involvement in sensitive or visible areas significantly impacts their quality of life despite not meeting traditional severity thresholds.
Video content above is prompted by the following:
- How common is undertreatment in psoriasis? What patient types are most commonly undertreated?
- Patients with skin of color, low socioeconomic status, low BSA but high-impact site involvement
- Gondo, 2024—31.7% of patients with moderate to severe disease treat psoriasis with OTC, complementary, or topical therapy only.
- In patients with mild objective measures for assessing psoriasis but high-impact location involvement, 32.8% of patients were only using OTC or topical therapy.
